{"schema_version":"secwatch.filing_event.v1","accession":"0001387131-22-010041","form_type":"8-K","ticker":"PLSE","cik":"0001625101","company_name":"PULSE BIOSCIENCES, INC.","filed_at":"2022-09-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.400014+00:00","generated_at":"2026-06-23T06:58:37.003528+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Pulse Biosciences appoints Kevin Danahy as CEO; grants 450,000 share option","bullets":["Kevin Danahy, previously Chief Commercial Officer, named CEO effective September 20, 2022.","Annual base salary of $400,000 and target bonus up to 100% of base salary.","Received option to acquire 450,000 shares vesting over 4 years at closing price on grant date.","Amended employment agreement includes 24-month severance if terminated within 2 years.","Danahy brings 20+ years medtech experience from Intuitive Surgical, Zimmer Biomet, Medtronic."],"urls":{"canonical":"https://secwatch.observer/filing/0001387131-22-010041","json":"https://secwatch.observer/filing/0001387131-22-010041.json","markdown":"https://secwatch.observer/filing/0001387131-22-010041.md","text":"https://secwatch.observer/filing/0001387131-22-010041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625101/000138713122010041/0001387131-22-010041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625101/000138713122010041/pulse-8k_092322.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T06:58:37.003528+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a99f20ec0c","claim":"Kevin Danahy was appointed as Chief Executive Officer at PULSE BIOSCIENCES, INC..","evidence_excerpt":"On September 23, 2022, in connection with the appointment of Kevin Danahy as Chief Executive Officer of Pulse Biosciences, Inc. (the “Company”), Mr. Danahy and the Company entered into an amendment (the “Danahy Amendment”) to Mr. Danahy’s employment agreement, dated February 9, 2022, which was initially entered into in connection with his appointment as Chief Commercial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1625101/000138713122010041/0001387131-22-010041-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}